Risperdal

You are here

Risperdal

Risperidone (trade name Risperdal and generics) is a second-generation a typical antipsychotic. It is a dopamine antagonist possessing anti-serotonergic, anti-adrenergic and anti-histaminergic properties.

The drug was developed by Janssen-Cilag, subsidiary of Johnson & Johnson, from 1988 to 1992 as an improvement from the typical antipsychotic and first approved by the FDA in 1994. Risperidone became available as a generic drug in October 2008.

Prescribed in the treatment of bipolar disorder and schizophrenia in adults and adolescents, is also used to treat irritability in children ages 5-to-16 years of age on the autism spectrum.

In February 2015, the first Risperdal trial went before a Philadelphia jury, resulting in a $2.5 million damage award for a 20 year old man who suffered gynecomastia breast growth after using the medication for treatment of autism when he was 8 years old.

Evidence presented at trial suggested that Johnson & Johnson's Janssen unit knew about the Risperdal gynecomastia risk as early as 2001, yet failed to warn consumers and the medical community. Over 1000+ cases are pending litigation in Philadelphia courts.

Evidence to look for in potential cases:

  1. 1. Risperdal usage by a Male in adolescence during 2006 to 2010.
  2. 2. Hyperprolactinemia, weight gain.
  3. 3. Treatment or surgery for Gynecomastia.

Medical Record Review and claim validation of Risperdal case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.

or Contact Us for a Free Consultation!
Contact Number with Country code
Any additional information you would like to provide.
This selection is for testing whether you are a human visitor and to prevent automated spam submissions.
All fields are mandatory.